Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

Sara Alosaimy; Sarah C J Jorgensen; Abdalhamid M Lagnf; Sarah Melvin; Ryan P Mynatt; Travis J Carlson; Kevin W Garey; David Allen; Veena Venugopalan; Michael Veve; Vasilios Athans; Stephen Saw; Christine N Yost; Susan L Davis; Michael J Rybak

doi:10.1093/ofid/ofaa051

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051. doi: 10.1093/ofid/ofaa051. eCollection 2020 Mar.

Authors

Sara Alosaimy¹, Sarah C J Jorgensen¹, Abdalhamid M Lagnf¹, Sarah Melvin¹, Ryan P Mynatt², Travis J Carlson³, Kevin W Garey³, David Allen⁴, Veena Venugopalan⁵, Michael Veve^{6

7}, Vasilios Athans⁸, Stephen Saw⁸, Christine N Yost⁹, Susan L Davis^{1

10}, Michael J Rybak^{1

2

11}

Affiliations

¹ Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
² Department of Pharmacy Services, Detroit Medical Center, Detroit, Michigan, USA.
³ College of Pharmacy, University of Houston, Houston, Texas, USA.
⁴ Department of Pharmacy, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.
⁵ College of Pharmacy, University of Florida, Gainesville, Florida, USA.
⁶ College of Pharmacy, University of Tennessee, Knoxville, Tennessee, USA.
⁷ University of Tennessee Medical Center, Knoxville, Tennessee, USA.
⁸ Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
⁹ Beaumont Hospital, Royal Oak, Michigan, USA.
¹⁰ Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA.
¹¹ Division of Infectious Diseases, Department of Medicine, School of Medicine, Wayne State University, Detroit, Michigan, USA.

Abstract

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

Keywords: Gram-negative infections; carbapenem-resistant Enterobacteriaceae; meropenem-vaborbactam; multidrug-resistant.